Go to
current issue
-
The landscape for radioligand therapies in oncology Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-06-03
Discover the world’s best science and medicine | Nature.com
-
Lowering pathological α-synuclein Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-06-02
Discover the world’s best science and medicine | Nature.com
-
Prolonging the antidepressant effects of ketamine Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-06-02
Discover the world’s best science and medicine | Nature.com
-
Towards a universal snake antivenom Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-06-02
Discover the world’s best science and medicine | Nature.com
-
Blocking a cell surface protein beats AML Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-06-02
Discover the world’s best science and medicine | Nature.com
-
The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-06-02
Arielle Elkrief, Reilly Pidgeon, Saman Maleki Vareki, Meriem Messaoudene, Bastien Castagner, Bertrand Routy -
A new drug target for NRAS(Q61) mutant-expressing cancers Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-29
Discover the world’s best science and medicine | Nature.com
-
Author Correction: GLP-1-based therapies for diabetes, obesity and beyond Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-28
Daniel J. DruckerCorrection to: Nature Reviews Drug Discovery https://doi.org/10.1038/s41573-025-01183-8, published online 25 April 2025.
-
Triggering ferroptosis in drug-tolerant cancer cells Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-27
Discover the world’s best science and medicine | Nature.com
-
Innovative Medicines Initiative public–private partnerships to enhance translational safety Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-22
Salah-Dine Chibout, Dominique Brees, Magda Chlebus, Philippe Detilleux, Loic Laplanche, Jonathan Moggs, Shashi K. Ramaiah, Jacques Richard, Gunnar Schütz, Nathalie Seigneuret, Thomas Steger-Hartmann, Elisabetta VaudanoInnovative Medicines Initiative projects focused on translational safety have developed a range of tools to improve preclinical assessments of potential drug toxicities, and demonstrated the value of integrating data from multiple companies.
-
Amylin takes another shot at the obesity prize Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-20
Drug developers are re-advancing amylin analogues for obesity, two decades since the FDA approved the first of these hormone mimetics for diabetes.
-
Targeting neutrophils for cancer therapy Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-15
Jeff W. Kwak, A. McGarry Houghton -
Is the FDA’s plan to phase out animal toxicity testing realistic? Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-15
Lorna Ewart, Chief Scientific Officer at Emulate, discusses the new opportunities and remaining challenges facing organs on chips.
-
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-13
Discover the world’s best science and medicine | Nature.com
-
The race to reset autoimmune diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-12
Discover the world’s best science and medicine | Nature.com
-
Hinge modifier approach opens door to drugging HECT E3 ligases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-09
Discover the world’s best science and medicine | Nature.com
-
A liver-directed route to reverse allergies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-08
Discover the world’s best science and medicine | Nature.com
-
FDA approves J&J’s FcRN blocker for generalized myasthenia gravis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-07
Discover the world’s best science and medicine | Nature.com
-
FDA approves cell-sheet-based gene therapy for severe skin disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-07
Discover the world’s best science and medicine | Nature.com
-
Application of new approach methodologies for nonclinical safety assessment of drug candidates Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-02
Mario Beilmann, Karissa Adkins, Harrie C. M. Boonen, Philip Hewitt, Wenyue Hu, Robert Mader, Susanne Moore, Payal Rana, Thomas Steger-Hartmann, Remi Villenave, Terry van Vleet -
Ramping up mitochondrial DNA replication Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-02
Discover the world’s best science and medicine | Nature.com
-
Targeting RNA structure to treat prostate cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-02
Discover the world’s best science and medicine | Nature.com
-
Lasso peptide targets drug-resistant bacteria Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-02
Discover the world’s best science and medicine | Nature.com
-
TIM-3 regulates microglial function Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-02
Discover the world’s best science and medicine | Nature.com
-
Understanding LAG3 immune checkpoint function Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-05-02
Discover the world’s best science and medicine | Nature.com
-
GLP-1-based therapies for diabetes, obesity and beyond Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-25
Daniel J. Drucker -
New antifungal tackles drug-resistant infections Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-24
Discover the world’s best science and medicine | Nature.com
-
The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-23
Discover the world’s best science and medicine | Nature.com
-
Enzymes in secondary pharmacology screening panels: is there room for improvement? Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-22
Monika Maciag, Vardan T. Karamyan -
Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-22
Friedemann Schmidt, Richard J. Brennan, Steve Jenkinson, Jean-Pierre Valentin -
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-17
Carolina M. Polonio, Kimberly A. McHale, David H. Sherr, David Rubenstein, Francisco J. Quintana -
Back to the drawing board for anhedonia drugs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-16
Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders.
-
Back to therapeutic modality basics Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-16
Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA.
-
FDA new drug approvals in Q1 2025 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-14
Discover the world’s best science and medicine | Nature.com
-
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-04
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian K. Fiske, Isabelle Le Ber, Kristin R. Wildsmith, Michael Schöll, Billy Dunn, Philip Scheltens -
Analysis of China-to-West pharmaceutical licensing deals in 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-04
Discover the world’s best science and medicine | Nature.com
-
Novel drug targets in 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-04
Discover the world’s best science and medicine | Nature.com
-
Trends in the drug target landscape for autoimmune diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-03
Discover the world’s best science and medicine | Nature.com
-
FDA approves siRNA drug for haemophilia prophylaxis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-02
Discover the world’s best science and medicine | Nature.com
-
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-04-01
Discover the world’s best science and medicine | Nature.com
-
Publisher Correction: Fibrosis: cross-organ biology and pathways to development of innovative drugs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-31
Florian Rieder, Laura E. Nagy, Toby M. Maher, Jörg H. W. Distler, Rafael Kramann, Boris Hinz, Marco PrunottoCorrection to: Nature Reviews Drug Discovery https://doi.org/10.1038/s41573-025-01158-9, published online 18 March 2025.
-
New antibiotic for urinary tract infections nabs FDA approval Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-31
Discover the world’s best science and medicine | Nature.com
-
Non-incretin peptide curbs appetite Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-28
Discover the world’s best science and medicine | Nature.com
-
Two routes to tamp down microglia in traumatic brain injury Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-26
Discover the world’s best science and medicine | Nature.com
-
Towards an oral norovirus vaccine Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-25
Discover the world’s best science and medicine | Nature.com
-
Small-molecule hypoxia therapy Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-25
Discover the world’s best science and medicine | Nature.com
-
Identifying novel antibiotic targets Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-25
Discover the world’s best science and medicine | Nature.com
-
Blocking ceramide signalling alleviates atherosclerosis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-25
Discover the world’s best science and medicine | Nature.com
-
Cannabinoid targets hidden pocket for safer pain relief Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-24
Discover the world’s best science and medicine | Nature.com
-
New approach methodologies: EU regulatory horizons Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-24
Mariana Edwards, Oriane Blanquie, Orla Moriarty, Sonja Beken, Falk EhmannNew approach methodologies (NAMs) have the potential to progressively transform medicines development by reducing reliance on animal testing while increasing the relevance of nonclinical data to patients. However, achieving regulatory acceptance of NAMs demands enhanced collaboration, clear guidance and continuous, science-based adaptation of the regulatory environment to accommodate emerging innovation
-
Insights into new approach methodology innovation: an EMA perspective Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-24
Discover the world’s best science and medicine | Nature.com
-
Life science ecosystems in Asia: biomedical innovation trends over the past decade Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-21
Discover the world’s best science and medicine | Nature.com
-
A new target for cancer cachexia Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-20
Discover the world’s best science and medicine | Nature.com
-
Computational drug repurposing: approaches, evaluation of in silico resources and case studies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-18
Ziaurrehman Tanoli, Adrià Fernández-Torras, Umut Onur Özcan, Aleksandr Kushnir, Kristen Michelle Nader, Yojana Gadiya, Laura Fiorenza, Aleksandr Ianevski, Markus Vähä-Koskela, Mitro Miihkinen, Umair Seemab, Henri Leinonen, Brinton Seashore-Ludlow, Marianna Tampere, Adelinn Kalman, Flavio Ballante, Emilio Benfenati, Gary Saunders, Swapnil Potdar, Ismael Gómez García, Ricard García-Serna, Carmine Talarico -
Fibrosis: cross-organ biology and pathways to development of innovative drugs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-18
Florian Rieder, Laura E. Nagy, Toby M. Maher, Jörg H. W. Distler, Rafael Kramann, Boris Hinz, Marco Prunotto -
Wrestling with the RAS cancer drug pipeline Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-14
Alice Shaw, Chief of Strategic Partnerships at Dana-Farber Cancer Institute, discusses the newly launched Center for RAS Therapeutics.
-
Accelerating precision oncology by converging pragmatic trials and real-world evidence Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-13
Kjetil Taskén, Piers MahonEngaging sufficient numbers of patients with cancers that have particular molecular characteristics is a key challenge in building evidence to support precision medicine in oncology. These challenges could be addressed by converging pragmatic clinical trials and hospital cancer informatics infrastructures to integrate cancer care and research.
-
Top companies and drugs by sales in 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-12
Discover the world’s best science and medicine | Nature.com
-
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-10
Discover the world’s best science and medicine | Nature.com
-
FDA approves MEK inhibitor for rare neurofibromas Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2025-03-10
Discover the world’s best science and medicine | Nature.com
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号